Inhibikase Therapeutics, Inc.
IKTDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How IKT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IKT-001 | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Frequently asked questions
What is in Inhibikase Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Inhibikase Therapeutics, Inc.'s (IKT) pipeline across Phase 3. Its lead program is IKT-001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Inhibikase Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Inhibikase Therapeutics, Inc. (IKT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IKT biotech catalysts?→
Add IKT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inhibikase Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.